Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(12):989-991; doi:10.1093/jnci/91.12.989
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lotan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotan, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 12, 989-991, June 16, 1999
© 1999 Oxford University Press

EDITORIAL

Aberrant Expression of Retinoid Receptors and Lung Carcinogenesis

Reuben Lotan

Correspondence to: Reuben Lotan, Ph.D., Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.

Lung cancer continues to be the leading cause of cancer deaths in the United States for both women and men (1). The alarmingly low 5-year relative survival rate (<14%) for all patients, regardless of stage at diagnosis, is a grim indication of the shortcomings of the current therapeutic approaches. Therefore, new strategies for preventing and treating lung cancer are urgently needed. One promising approach is chemoprevention with natural and synthetic vitamin A analogues known as retinoids (2,3). The rationale for using retinoids for lung cancer prevention is based on their ability to regulate the growth and differentiation of aerodigestive tract epithelial cells (2) and to prevent lung carcinogenesis in animal models (4). Furthermore, clinical trials have demonstrated the efficacy of retinoids in suppressing oral high-risk noncancerous lesions and reducing second primary cancers in patients with prior head and neck or . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
Y. T. Kim, S. H. Lee, S. W. Sung, and J. H. Kim
Can Aberrant Promoter Hypermethylation of CpG Islands Predict the Clinical Outcome of Non-Small Cell Lung Cancer After Curative Resection?
Ann. Thorac. Surg., April 1, 2005; 79(4): 1180 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Kim, H. Lee, H. Kim, Y. M. Shim, J. Han, J. Park, and D.-H. Kim
Promoter Methylation of Retinoic Acid Receptor Beta 2 and the Development of Second Primary Lung Cancers in Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2004; 22(17): 3443 - 3450.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. H. Dragnev, D. Stover, and E. Dmitrovsky
Lung Cancer Prevention: The Guidelines
Chest, January 1, 2003; 123 (2009): 60S - 71S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
K. Million, F. Tournier, O. Houcine, P. Ancian, U. Reichert, and F. Marano
Effects of Retinoic Acid Receptor-Selective Agonists on Human Nasal Epithelial Cell Differentiation
Am. J. Respir. Cell Mol. Biol., December 1, 2001; 25(6): 744 - 750.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. K. Virmani, A. Rathi, S. Zochbauer-Muller, N. Sacchi, Y. Fukuyama, D. Bryant, A. Maitra, S. Heda, K. M. Fong, F. Thunnissen, et al.
Promoter Methylation and Silencing of the Retinoic Acid Receptor-{beta} Gene in Lung Carcinomas
J Natl Cancer Inst, August 16, 2000; 92(16): 1303 - 1307.
[Abstract] [Full Text] [PDF]